CompletedPhase 2NCT04107727
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PETHEMA Foundation
- Principal Investigator
- Pau MontesinosHospital Universitari i Politecnic La Fe
- Intervention
- Quizartinib(drug)
- Enrollment
- 273 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2019 – 2025
Study locations (30)
- Complejo Hospitalario Universitario de A Coruña, Santiago de Compostela, A Coruña, Spain
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain
- Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
- Hospital General Univesitario de Castellón, Castellon, Castellón, Spain
- Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
- Hospital Universitario Quirón Salud Madrid, Pozuelo de Alarcón, Madrid, Spain
- Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
- Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
- Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
- Hospital Universitario de Basurto, Bilbao, Vizcaya, Spain
- Hospital Universitario de Galdakao, Galdakao, Vizcaya, Spain
- Complejo Hospitalario de Albacete, Albacete, Spain
- Hospital General Universitario de Alicante, Alicante, Spain
- Hospital Universitari Vall Hebron, Barcelona, Spain
- Hospital Universitario de Burgos, Burgos, Spain
- +15 more locations on ClinicalTrials.gov
Collaborators
Dynamic Science S.L. · Daiichi Sankyo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04107727 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo